Tempus AI’s TEM stock has surged nearly 13% since its second-quarter 2025 earnings release. The quarter saw strong top-line ...

Over the past two years, one of the most interesting healthcare companies to go public is none other than Tempus AI (NASDAQ: ...

Tempus AI reported an impressive revenue increase of 89.6%, reaching $314.6 million. The Genomics segment led the charge with a 115% rise to $241.8 million, while Data and Services revenue grew by ...

Tempus AI raises 2025 revenue outlook again after strong Q2 growth in genomics and AI-driven oncology solutions.

Bullish option flow detected in tempus AI ( TEM) Inc Class A with 45,265 calls trading, 2x expected, and implied vol increasing over 1 point to 72.64%. Aug-25 70 calls and Aug-25 75 calls are the most ...

The collaboration will fund early-stage clinical development of SB-4826, CIT’s first-in-class SUMO E1 inhibitor, for patients ...

Bioventus Inc. (NASDAQ:BVS) is one of the best medical device stocks to buy according to analysts. On August 7, Craig-Hallum ...